EXIT071
Leiden
About EXIT071
EXIT071 develops technology to hack intercellular communication. Their microfluidic technology is applied for the analysis of exosomes in therapeutics and diagnostics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $2.4M
- Funding stage: Seed
- Last round: Seed (Mar 2025)
- Website: exit071.com
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/exit071-138188 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.